Entering text into the input field will update the search result below

Encouraging data on Amgen's AMG 510 stokes Mirati, up 9%

Jul. 31, 2019 11:12 AM ETMirati Therapeutics, Inc. (MRTX) StockMRTXBy: Douglas W. House, SA News Editor
  • Mirati Therapeutics (MRTX +9.3%) is up on below-average volume in apparent response to Amgen's R&D update during its Q2 earnings call after the close yesterday. Preliminary data from a Phase 1/2 clinical trial evaluating AMG 510, a KRAS G12C inhibitor, in patients with solid tumors showed tumor responses in colorectal and appendiceal patients (Slide #29 in presentation). In June, Amgen announced data from the study that included responses in lung cancer patients.
  • Mirati is also developing a KRAS G12C inhibitor, MRTX849, also in Phase 1/2 development.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
MRTX--
Mirati Therapeutics, Inc.